Tags: EU | Switzerland | Novartis | Cancer | Trial

Novartis Takes $120 Million Hit from Failed Cancer Drug Trial

Thursday, 11 Nov 2010 10:56 AM

Swiss pharmaceutical company Novartis AG says it has halted late-stage development of a new drug for lung cancer and will write off $120 million in the fourth quarter as a result.

The company, based in Basel, said Thursday the experimental drug ASA404 failed to significantly extend survival rates in combination with chemotherapy for patients with advanced non-small cell lung cancer.

Novartis had licensed the drug also known as vadimezan from Britain's Antisoma PLC in 2007.

Shares in Novartis dipped 0.6 percent to 54.70 Swiss francs ($56.40) on the Zurich exchange.

© Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

   
1Like our page
2Share
Companies
Swiss pharmaceutical company Novartis AG says it has halted late-stage development of a new drug for lung cancer and will write off $120 million in the fourth quarter as a result.The company, based in Basel, said Thursday the experimental drug ASA404 failed to significantly...
EU,Switzerland,Novartis,Cancer,Trial
90
2010-56-11
Thursday, 11 Nov 2010 10:56 AM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved